AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint - BioPharm International

2026-01-30 - 02:45

AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint BioPharm International